EagleClaw Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.28M | Sell |
9,190
-200
| -2% | -$28K | 0.18% | 87 |
|
|
2025
Q4 | $1.15M | Buy |
9,390
+800
| +9% | +$97.2K | 0.17% | 89 |
|
|
2025
Q3 | $953K | Hold |
8,590
| – | – | 0.13% | 95 |
|
|
2025
Q2 | $952K | Sell |
8,590
-1,070
| -11% | -$114K | 0.14% | 92 |
|
|
2025
Q1 | $1.08M | Buy |
9,660
+600
| +7% | +$61.9K | 0.17% | 92 |
|
|
2024
Q4 | $837K | Hold |
9,060
| – | – | 0.13% | 92 |
|
|
2024
Q3 | $760K | Buy |
9,060
+325
| +4% | +$24.8K | 0.13% | 94 |
|
|
2024
Q2 | $599K | Hold |
8,735
| – | – | 0.11% | 97 |
|
|
2024
Q1 | $640K | Sell |
8,735
-490
| -5% | -$37.7K | 0.12% | 98 |
|
|
2023
Q4 | $747K | Hold |
9,225
| – | – | 0.16% | 91 |
|
|
2023
Q3 | $691K | Sell |
9,225
-550
| -6% | -$42.3K | 0.16% | 90 |
|
|
2023
Q2 | $753K | Sell |
9,775
-300
| -3% | -$23.9K | 0.17% | 92 |
|
|
2023
Q1 | $836K | Sell |
10,075
-900
| -8% | -$74.5K | 0.2% | 84 |
|
|
2022
Q4 | $942K | Hold |
10,975
| – | – | 0.23% | 81 |
|
|
2022
Q3 | $677K | Buy |
10,975
+200
| +2% | +$12.6K | 0.19% | 86 |
|
|
2022
Q2 | $666K | Buy |
10,775
+300
| +3% | +$18.6K | 0.18% | 84 |
|
|
2022
Q1 | $623K | Sell |
10,475
-3,350
| -24% | -$214K | 0.14% | 93 |
|
|
2021
Q4 | $1M | Sell |
13,825
-29,045
| -68% | -$2M | 0.22% | 81 |
|
|
2021
Q3 | $2.99M | Buy |
42,870
+516
| +1% | +$36.3K | 0.77% | 41 |
|
|
2021
Q2 | $2.92M | Buy |
42,354
+1,092
| +3% | +$72.9K | 0.75% | 43 |
|
|
2021
Q1 | $2.67M | Buy |
41,262
+2,149
| +5% | +$139K | 0.77% | 41 |
|
|
2020
Q4 | $2.27M | Sell |
39,113
-4,079
| -9% | -$246K | 0.72% | 46 |
|
|
2020
Q3 | $2.73M | Buy |
43,192
+170
| +0.4% | +$11.8K | 0.96% | 31 |
|
|
2020
Q2 | $3.31M | Sell |
43,022
-1,100
| -2% | -$84.3K | 1.28% | 24 |
|
|
2020
Q1 | $3.29M | Buy |
44,122
+370
| +0.8% | +$25.6K | 1.55% | 21 |
|
|
2019
Q4 | $2.84M | Buy |
43,752
+3,925
| +10% | +$256K | 1.04% | 32 |
|
|
2019
Q3 | $2.52M | Buy |
39,827
+7,025
| +21% | +$459K | 1.03% | 30 |
|
|
2019
Q2 | $2.22M | Buy |
32,802
+6,225
| +23% | +$410K | 0.97% | 31 |
|
|
2019
Q1 | $1.73M | Buy |
26,577
+275
| +1% | +$18.3K | 0.79% | 43 |
|
|
2018
Q4 | $1.65M | Sell |
26,302
-1,353
| -5% | -$94.6K | 0.87% | 39 |
|
|
2018
Q3 | $2.14M | Buy |
27,655
+4,405
| +19% | +$333K | 0.94% | 31 |
|
|
2018
Q2 | $1.65M | Sell |
23,250
-75
| -0.3% | -$5.3K | 0.8% | 41 |
|
|
2018
Q1 | $1.76M | Buy |
23,325
+900
| +4% | +$71.5K | 0.89% | 38 |
|
|
2017
Q4 | $1.61M | Buy |
22,425
+400
| +2% | +$30.4K | 0.81% | 49 |
|
|
2017
Q3 | $1.78M | Buy |
22,025
+3,200
| +17% | +$245K | 1% | 35 |
|
|
2017
Q2 | $1.33M | Sell |
18,825
-575
| -3% | -$38.3K | 0.78% | 51 |
|
|
2017
Q1 | $1.32M | Sell |
19,400
-275
| -1% | -$19.3K | 0.79% | 52 |
|
|
2016
Q4 | $1.41M | Sell |
19,675
-950
| -5% | -$70.6K | 0.89% | 42 |
|
|
2016
Q3 | $1.64M | Buy |
20,625
+675
| +3% | +$54.8K | 1.05% | 37 |
|
|
2016
Q2 | $1.66M | Buy |
19,950
+3,625
| +22% | +$322K | 1.11% | 32 |
|
|
2016
Q1 | $1.5M | Buy |
16,325
+3,825
| +31% | +$345K | 1.02% | 36 |
|
|
2015
Q4 | $1.26M | Buy |
12,500
+500
| +4% | +$52K | 0.84% | 45 |
|
|
2015
Q3 | $1.18M | Buy |
12,000
+1,650
| +16% | +$183K | 0.83% | 44 |
|
|
2015
Q2 | $1.21M | Buy |
10,350
+925
| +10% | +$101K | 0.78% | 48 |
|
|
2015
Q1 | $925K | Buy |
9,425
+400
| +4% | +$40.6K | 0.6% | 55 |
|
|
2014
Q4 | $850K | Buy |
9,025
+550
| +6% | +$56.9K | 0.56% | 58 |
|
|
2014
Q3 | $901K | Buy |
8,475
+200
| +2% | +$19.6K | 0.61% | 56 |
|
|
2014
Q2 | $686K | Buy |
+8,275
| New | +$644K | 0.47% | 65 |
|
Other funds holding GILD
VCM
VPM
EagleClaw Capital Management's GILD Position: Q1 2026 in Review
EagleClaw Capital Management reduced its Gilead Sciences (GILD) stake by 2.1% in Q1 2026, selling an estimated $28K and leaving 9,190 shares worth $1.28M. The position accounts for 0.18% of the portfolio, ranked #87.
EagleClaw Capital Management first reported a position in GILD in Q2 2014 and has held it in 48 quarters since. The position peaked at $3.31M in Q2 2020. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- EagleClaw Capital Management held 9,190 shares of Gilead Sciences worth $1.28M as of Q1 2026.
- EagleClaw Capital Management sold 200 Gilead Sciences shares in Q1 2026, an estimated $28K.
- Gilead Sciences made up 0.18% of EagleClaw Capital Management's portfolio in Q1 2026, its #87 holding.
- EagleClaw Capital Management first reported a position in Gilead Sciences in Q2 2014 and has held it in 48 quarters since.
- EagleClaw Capital Management's Gilead Sciences position peaked at $3.31M in Q2 2020.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on EagleClaw Capital Management's 13F filing for Q1 2026, filed 8 May 2026.